Savant Capital’s PTC Therapeutics PTCT Stock Holding History

Savant Capital’s Portfolio PTCT Stock Details PTCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-4,648	Closed	-$210K	–	1355
2024 Q4	$210K	Buy	+4,648	New	+$199K	﹤0.01%	1300

Other funds holding PTCT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Savant Capital's PTCT Position: Q1 2025 in Review

Savant Capital sold out of PTC Therapeutics (PTCT) in Q1 2025, closing a stake of 4,648 shares — an estimated $210K sold.

Savant Capital first reported a position in PTCT in Q4 2024 and held it in 1 quarter. The position peaked at $210K in Q4 2024. 260 funds tracked by Wall St. Rank hold PTCT as of Q1 2025.

Savant Capital reported no remaining PTC Therapeutics position as of Q1 2025 after selling out during the quarter.
Savant Capital sold 4,648 PTC Therapeutics shares in Q1 2025, an estimated $210K.
Savant Capital first reported a position in PTC Therapeutics in Q4 2024 and held it in 1 quarter.
Savant Capital's PTC Therapeutics position peaked at $210K in Q4 2024.
260 funds tracked by Wall St. Rank held PTC Therapeutics as of Q1 2025.

Based on Savant Capital's 13F filing for Q1 2025, filed 8 May 2025.